Today’s Stock Alert: How Analysts Feel About HTG Molecular Diagnostics Inc After Making All-Time Low?

Today's Stock Alert: How Analysts Feel About HTG Molecular Diagnostics Inc After Making All Time Low?

The stock of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) reached all time low today, Nov, 3 and still has $1.71 target or 14.00% below today’s $1.99 share price. This indicates more downside for the $13.71 million company. This technical setup was reported by Barchart.com. If the $1.71 PT is reached, the company will be worth $1.92 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. The stock decreased 5.24% or $0.11 on November 3, hitting $1.99. About 212,637 shares traded hands. HTG Molecular Diagnostics Inc (NASDAQ:HTGM) has declined 27.34% since April 1, 2016 and is downtrending. It has underperformed by 28.55% the S&P500.

Analysts await HTG Molecular Diagnostics Inc (NASDAQ:HTGM) to report earnings on November, 10.

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) Ratings Coverage

Out of 2 analysts covering HTG Molecular Diagnostics (NASDAQ:HTGM), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. HTG Molecular Diagnostics has been the topic of 3 analyst reports since August 24, 2015 according to StockzIntelligence Inc. Canaccord Genuity maintained HTG Molecular Diagnostics Inc (NASDAQ:HTGM) rating on Tuesday, November 24. Canaccord Genuity has “Buy” rating and $10 price target. The stock of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) earned “Buy” rating by Canaccord Genuity on Monday, August 24. The stock has “Buy” rating given by Rodman & Renshaw on Monday, August 22.

According to Zacks Investment Research, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona.”

More important recent HTG Molecular Diagnostics Inc (NASDAQ:HTGM) news were published by: Quotes.Wsj.com which released: “News HTG Molecular Diagnostics Inc.HTGM” on May 01, 2015, also Globenewswire.com published article titled: “Don Hardison Joins the Board of Directors for HTG Molecular Diagnostics”, Seekingalpha.com published: “HTG Molecular Diagnostics’ (HTGM) CEO TJ Johnson on Q1 2016 Results – Earnings …” on May 13, 2016. More interesting news about HTG Molecular Diagnostics Inc (NASDAQ:HTGM) was released by: Globenewswire.com and their article: “James (Jim) LaFrance Joins the Board of Directors of HTG Molecular Diagnostics” with publication date: December 02, 2015.

HTGM Company Profile

HTG Molecular Diagnostics, Inc., incorporated on December 14, 2000, is a commercial-stage firm that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company’s HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company’s HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment